Hypofractionated radiotherapy for advanced non-small-cell lung cancer: Is the LINAC half full?

Journal of Clinical Oncology

Volumn 22, Issue 5, 2004, Pages 765-768

  Bogart, Jeffrey A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; EDITORIAL; EUROPE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; NORTH AMERICA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; CANCER STAGING; COMPARATIVE STUDY; FEMALE; LUNG TUMOR; MALE; MORTALITY; NOTE; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE; SURVIVAL; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542608361     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.938     Document Type: Editorial

References (31)

1. Thames HD Jr: Early fractionation methods and the origins of the NSD concept. Acta Oncol 27:89-103, 1988
2. Regaud C: Principes du traitement des épithéliomas épidermoides par les radiations. Application aux épidermoides de la peau et de la bouche. J Radiol Electrol 7:297, 1927
3. Coutard H: Principles of x-ray therapy of malignant disease. Lancet 2:1, 1934
4. Abratt RP, Bogart JA, Hunter A: Hypofractionated irradiation for non-small cell lung cancer. Lung Cancer 36:225-233, 2002
5. Pirtoli L, Bindi M, Bellezza A, et al: Unfavorable experience with hypofractionated radiotherapy in unresectable lung cancer. Tumori 78:305-310, 1992
6. Roach M III, Gandara DR, Yuo H-S, et al: Radiation cancer: Analysis of prognostic factors. J Clin Oncol 13:2606-2612, 1995
7. Sundstrom S, Bremnes R, Aasebo U, et al: The effect of hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: Results from a national phase III trial. J Clin Oncol 22:801-810, 2004
8. Toy E, Macbeth F, Coles B, et al: Palliative thoracic radiotherapy for non-small-cell lung cancer: A systematic review. Am J Clin Oncol 26:112-120, 2003
9. Bezjak A, Dixon P, Brundage M, et al: Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC. 15). Int J Radiat Oncol Biol Phys 54:719-728. 2002
10. Gaze MN, Kelly CG, Kerr GR, et al: Fractionated thoracic radiotherapy gives better symptom relief in patients with non-small cell lung cancer. EJC 37:S29, 2001 (suppl 6)
11. Simpson JR, Francis ME, Perez-Tamkayo R, et al: Palliative radiotherapy for inoperable carcinoma of the lung: Final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys 11:751-758, 1985
12. Reinfuss M, Glinski B, Kowalska T. et al: Radiothérapie du cancer bronchique non à petite cellules de stade III, inopérable, asymptomatique. Résultats définitifs d'un essai prospectif randomisé (240 patients). Cancer Radiother 3:475-479, 1999
13. Bleehan NM, Girling DJ, Fayers PM, et al: Inoperable non-small-cell lung cancer (NSCLC): A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 63:265-270, 1991
14. Bleehan NM, Girling DJ, Machin D, et al: A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer 65:934-941, 1992
15. Macbeth F, Bolger JJ, Hopwood P, et al: Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status: Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 8:167-175, 1996
16. Rees GJ, Devrell CE, Barley VL, et al: Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol) 9:90-95, 1997
17. Abratt RP, Shepard LJ, Mameena Salton DG: Palliative radiation for stage 3 non-small cell lung cancer - A prospective study of two moderately high dose regimens. Lung Cancer 13:137-143, 1995
18. Teo P, Tai H, Choy D, et al: A Randomised Study on Palliative Radiation Therapy for Inoperable Non Small Cell Carcinoma of the Lung. Int J Radiat Oncol Biol Phys 14:867-871, 1988
19. Nestle U, Nieder C, Walter K, et al: A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 Gy: Results of a randomized equivalence study. Int J Radiat Oncol Biol Phys 48:95-103, 2000
20. Hartsell WE, Scott C, Bruner DW, et al: Phase III randomized trial of 8 Gy in 1 fraction vs. 30 Gy in 10 fractions for palliation of painful bone metastases: Preliminary results of RTOG 97-14. Int J Radiat Oncol Biol Phys 57:S124, 2003 (suppl 2)
21. Marino P, Pampallona S, Preatoni A, et al: Chemotherapy vs. supportive care in advanced non-small-cell lung cancer: Results of a meta-analysis of the literature. Chest 106:861-865, 1994
22. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
23. The Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival in elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
24. Lilenbaum RC, Herndon J, List M, et al: Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 21:1a, 2002 (abstr 2)
25. Falk SJ, White RJ, Hopwood P, et al: Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: Results of a randomized controlled trial. BMJ 325:465-468, 2002
26. Anderson H, Hopwood R, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome. Br J Cancer 83:447-453, 2000
27. Curran WJ, Scott CB, Langer CJ, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003 (abstr 2499)
28. Perez CA, Stanley K, Rubin P, et al: A prospective randomized study of various irradiation doses and fractionation scheduled in the treatment of inoperable non-oat cell carcinoma of the lung: Preliminary report by the Radiation Therapy Oncology Group. Cancer 45:2744-2753, 1980
29. Videtic GMM, Johnson BE, Friedlin B, et al: The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. Proc Am Soc Clin Oncol 22:636, 2003 (abstr 2557)
30. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: A randomized multicentre trial. CHART Steering Committee. Lancet 350:161-165, 1977
31. Belani CP, Wang W, Johnson DH, et al: Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and B non-small-cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Proc Am Soc Clin Oncol 22:622, 2003 (abstr 2500)